Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound

The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function ( p =0.038). Th...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2021-04, Vol.170 (6), p.774-777
Main Authors: Barchukov, V. V., Tsorin, I. B., Vititnova, M. B., Efimova, A. O., Likhosherstov, A. M., Mokrov, G. V., Kryzhanovskii, S. A.
Format: Article
Language:English
Subjects:
Analysis
Animal experimentation
Biomedical and Life Sciences
Biomedicine
Cell Biology
Congestive heart failure
Heart attack
Heart failure
Internal Medicine
Laboratory Medicine
Myocardial infarction
New Drugs
Pathology
Trimetazidine
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function ( p =0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-021-05152-0